Company Profile

Product Development

Company Profile

 

Management

Board of Directors

Scientific Advisory Board

Strategic Partners

 

Management
 

Phil Speros

Phil Speros, PhD, MBA
Chief Executive Officer
Co-founder of Halsa, holds a Ph.D. from The Johns Hopkins University in biochemistry, and has four U.S. Patents. He also holds an MBA from The McCombs School of Business of The University of Texas at Austin. Phil has spent nineteen years in entrepreneurial ventures and technical consulting in the arena of technology commercialization; he has founded or co-founded seven previous ventures.

 

 

Ken Laderman, PhD
Chief Scientific Officer
Co-founder of Halsa, holds a Ph.D. in molecular biology from Johns Hopkins, received a postdoctoral fellowship and research faculty appointment at Cal Tech, as well as a postdoctoral fellowship at UCLA. Ken has twelve years of biotechnology experience with Cetus (acquired by Chiron), Takara (Japan) and Alpha, and at City of Hope. Ken holds three U.S. Patents. He has exact domain expertise in cell culture, protein purification, FDA compliant GLP/GMP operations, and biologics manufacturing.

 


Board of Directors

 

 

David Anderson
Mr. Anderson has more than 20 years of experience as an executive, advisor and investor in the life sciences industry. He is Chairman of the Board for both Nanospectra Biosciences, Inc., a company developing life science applications for nanoshells, a new class of materials, and PLx Pharma, Inc., a company developing GI-safer NSAIDS. From 2001 to 2009, he was the CEO and Chairman of the Board of MithraGen, a cancer vaccine company, and from 1987 to 2001 was at Tanox, Inc., serving for 8 years as the Chief Operations Officer and a director. He also serves as an advisor to other early stage life sciences companies. Prior to joining Tanox in 1987, Mr. Anderson was engaged in the private practice of law, with a focus in the areas of mergers and acquisitions, financing transactions and intellectual property licensing.
 

 

Gary Cadenhead, Ph.D.

Gary Cadenhead, Ph.D.

Chairman
Dr Cadenhead is the director of the Master of Science in the Science of Technology Commercialization (MSSTC) Program at the IC˛ Institute. Prior to joining The University of Texas in 1980, Dr. Cadenhead held faculty positions at Stanford University, UCLA, and the University of California at Santa Barbara. He graduated Phi Beta Kappa from Southern Methodist University, earned an MBA from Harvard University, and received his PhD in accounting from Stanford University. In 1995, the Kauffman Foundation and the Entrepreneur of the Year Institute recognized him as one of the Top Ten Entrepreneurship Educators of the Year. In a 2003 survey of entrepreneurship directors commissioned by Entrepreneur magazine, Dr. Cadenhead was recognized as one of the three top directors of entrepreneurship programs in the United States. A CPA licensed in the State of Texas, he had auditing experience with Deloitte Haskins & Sells, now Deloitte. He serves on the advisory board of The Journal of Private Equity.

 

 

James Cox
Mr. Cox served as Chairman of the Texas Lottery Commission from 2002 to 2009. He also served on the Texas General Services Commission from 1999 to 2002. Cox was president of the Casino and Aviation Groups of the Estate of Howard Hughes, and president and CEO of Hydrolab Corporation. He was previously a Deloitte accounting and auditing partner. He is a member of the American Institute of Certified Public Accountants (AICPA) and served on the Gaming Industry Special Committee, which wrote the AICPA’s Audit Guide for Casinos. Cox chairs the board of directors of the Texas Methodist Foundation. He received bachelor’s and master’s degrees in business administration from the University of Texas at Austin, where he also did doctoral work in American Studies.

 

  Doug Baum

Doug Baum
Douglas R. Baum has 20 years of experience serving in a number of business development and executive management positions within the life sciences industry. Baum is a co-founder and COO of MacuCLEAR Corporation (www.macuclear.com), a specialty clinical stage pharmaceutical company focused on developing treatments for various vascular disorders of the eye. Baum also serves on the Board of Directors for MacuCLEAR and Xeris Pharmaceuticals. Baum previously served as Vice President, Global Corporate Development at Premier Research Group (PRG), Inc. a global contract research organization serving the pharmaceutical, biotechnoogy and medical device industries. In 2006 PRG acquired SCIREX Corporation where Mr. Baum served as Executive Vice President & General Manager, Early Drug Development where he was responsible for all strategic, commercial, organizational and financial aspects of SCIREX's early drug development business unit. Prior to this Mr. Baum lead the Business Development and Strategy functional area within SCIREX, which at the time was wholly owned by Omnicom Group, a Fortune 400 company (NYSE: OMC). Mr. Baum has worked on the development of 17 FDA approved products and has authored/presented study results from over 15 pivotal clinical trials at various scientific meetings throughout the US, Europe and Australia. Mr. Baum obtained his Bachelor's of Business Administration degree from the McCombs Business School at the University of Texas at Austin (UT), as well as, a Master’s of Science in Technology Commercialization degree from UT. Baum began his career in an international position living and working in Japan .

 



Scientific Advisory Board
 

John Foreyt, Ph.D.

John Foreyt, Ph.D.
Dr. Foreyt is a Professor in the Department of Medicine and the Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine, Houston, Texas. He also is the Director of the DeBakey Heart Center's Behavioral Medicine Research Center. Dr Foreyt received his B.S. in psychology from the University of Wisconsin and his M.S. and Ph.D.in clinical psychology in 1969 from Florida State University. He has served as a member of the National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health; The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity, Food and Nutrition Board, Institute of Medicine, National Academy of Sciences; and The Expert Panel on the Identification, Evaluation, and Treatment of Adults at High Risk for Cardiovascular Disease, National Institutes of Health, NHLBI. He is currently a member of the editorial boards of: Eating Disorders; Obesity Research; Journal of Cardiopulmonary Rehabilitation; American Journal of Health Promotion; Journal of Behavioral Medicine; American Journal of Health Promotion; and Diabetes, Obesity and Metabolism. Dr. Foreyt has published extensively in the areas of diet modification, cardiovascular risk reduction, eating disorders, and obesity. He has published 17 books and more than 260 articles.
 

Theresa Fossum, DVM

Theresa Fossum, DVM
Dr Fossum is currently the Associate Professor and Chief of Surgery at the Department of Small Animal Medicine and Surgery at the College of Veterinary Medicine, Texas A&M University and Director of the Texas Institute of Preclinical Studies (TIPS). Dr Fossum is a graduate of Washington State University, where she obtained her Doctor in Veterinary Medicine degree in 1982. Dr Fossum also obtained her Masters in Surgery in 1986 at the Ohio State University, Columbus. After completing two degrees, she continued her studies and completed her Ph.D at the Texas A&M University, in 1992. Dr Fossum has spent many years studying in the United States and now and specializes in Small Animal Surgery. She is currently involved with many research funding projects including In vivo evaluation of the DeBakey ventricular assist device in a sheep model. Dr Fossum is the editor of Small Animal Surgery, and has written more than one hundred articles, for various journals.

 

Professor Michael J. Tisdale

Professor Michael J. Tisdale
Dr Tisdale is a world-renowned cancer and metabolic disease researcher who graduated from Hull University in 1967 with a BSc (lst Class Honours) (Chemistry), followed by a PhD (Chemistry), from London, 1970 and a DSc (Cancer Biochemistry), London, 1983. He joined the Cancer Research Campaign Experimental Chemotherapy Group in the Department of Pharmacy at Aston University as Senior Research Fellow in October 1980. Prior to that , Dr Tisdale spent 8 years as Lecturer in the Department of Biochemistry at St Thomas’s Hospital Medical School, University of London, one year as Scientific Officer at Rothamstead Experimental Station, Harpenden and one year as MRC Fellow at the Institute of Cancer Research. Dr Tisdale’s research focuses include: cancer cachexia, its mechanism and treatment and the treatment of obesity and type 2 diabetes.

 

Robert Kramer, MD

Robert Kramer, M.D.
Presently: SENIOR MEDICAL ADVISOR, NTEC Biotechnology Incubator, Frisco, Texas, CHIEF MEDICAL OFFICER, Nutritox, Inc; TelaDoc, Inc.; Imadulation/Sound Solutions for Health, Inc., CORPORATE MEDICAL DIRECTOR, Zale Corporation, Texas Industries, Wyndham International, Prentiss Properties; ACS, Inc., Perot Systems, Brinker International, CONSULTANT PHYSICIAN; Dallas Museum of Art, Dallas Theater Center, Dallas Symphony, Dallas Opera, Dallas Childrens’ Theater, Dallas Children’s Museum, Hotel Crescent Court, Ritz Carlton Hotel Dallas, CONSULTANT, International Center for Toxicology and Medicine and Member of Mold-Medicine Scientific Group, BOARD or MEDICAL ADVISORY BOARD: Department of Biomedical Engineering, UT Austin; Gryphon Technologies, Inc;SenoMedical Systems, Patton Surgical Instruments, Secure Symbology, Inc; Veroscan, Inc; Encentuate, Inc; Torquin LLC; CareGain, Inc; Medical Present Value; TelaDoc, Inc.; Delphi Health Systems, Inc; NTEC; BMSI; TotalChart, Inc; Pardalis, Inc; Holocaust Studies Program, UT Dallas; St. Marks School of Texas; Reading and Radio Resource; Home Health Services of Dallas; Texas Healthcare & Bioscience Institute Foundation (THBI); Previously: CLINICAL PROFESSOR OF PEDIATRICS AND PULMONOLOGY, UT Southwestern Medical Center (Ret.), CHAIRMAN, Department of Pediatrics , Baylor University Medical Center, (Ret.), DISTINGUISHED ADJUNCT PROFESSOR, University of Dallas, Graduate School of Management, FELLOW, AMERICAN ACADEMY OF PEDIATRICS, Member Pulmonology Section, DIPLOMATE, American Board of Pediatrics. MEMBER, American Association for the Advancement of Science; New York Academy of Science, FOUNDING PARTNER, Pediatric Associates of Dallas; Baylor Pediatric Center, DISTINGUISHED FELLOW, ICC Institute, McCombs Business School, UT Austin. Medical Director of the Health Care Consulting Practice, Coopers and Lybrand,Founding Partner, DecisionHealth Consultancy; Director of Life Sciences, Technological Partners; Distinguished Adjunct Professor, University of Dallas Graduate School of Management; Founding Partner, Pediatric Associates of Dallas; Baylor Pediatric Center; Faculty at UT Southwestern Medical Center. Board Membership: Itasca Ventures; the Hockaday School; Brown University Alumni Trustee; Susan Komen Foundation; National Cystic Fibrosis Foundation Research and Development Council;

 

 



Strategic Partners

 

Aston University

 

Halsa believes strategic alliances can augment product development and advance projects towards commercialization. For more information regarding partnership opportunities, please contact us: alliance@halsapharma.net

 

Metabolic Diseases

News

 

 

Sitemap  | Privacy PolicyTerms of Use